SCHEMBL17766945

SCHEMBL17766945

CCC(NC(=O)Cn1nnc2ccccc2c1=O)c1ccc(Br)cc1

nearest known ligand 0.83

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ GPR139 Q6DWJ6 20/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17767163 0.91 GPR139 (1.00) GPR139
SCHEMBL17766926 0.90 GPR139 (0.83) GPR139
SCHEMBL17767099 0.88 GPR139 (0.80) GPR139
SCHEMBL17767143 0.87 GPR139 (1.00) GPR139
SCHEMBL17767216 0.87 GPR139 (1.00) GPR139
SCHEMBL17767156 0.87 GPR139 (1.00) GPR139
SCHEMBL17767152 0.87 GPR139 (1.00) GPR139
SCHEMBL17766961 0.84 GPR139 (1.00) GPR139
SCHEMBL17766964 0.84 GPR139 (1.00) GPR139
SCHEMBL17766999 0.84 GPR139 (0.74) GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3536324-B1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 TAKEDA PHARMACEUTICALS CO (JP) 2021-10-06 — — EP disclosed
US-10561662-B2 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-18 — — US disclosed
EP-3536324-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 Takeda Pharmaceutical Company Limited (JP) 2019-09-11 — — EP disclosed
EP-3221298-B1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE DERIVATIVES AS MODULATORS OF GPR139 TAKEDA PHARMACEUTICALS CO (JP) 2019-04-03 — — EP disclosed
US-20190070187-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 TAKEDA CALIFORNIA, INC. 2019-03-07 — — US disclosed
EP-3221298-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 Takeda Pharmaceutical Company Limited (JP) 2017-09-27 — — EP disclosed
US-9770450-B2 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-26 — — US disclosed
US-20170095480-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2017-04-06 — — US disclosed
US-9556130-B2 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-01-31 — — US disclosed
US-20160145218-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 TAKEDA CALIFORNIA, INC. 2016-05-26 — — US disclosed
WO-2016081736-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070187-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 GPR139, GPR3, GPR84 GPR139 1/4885
US-20170095480-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139 GPR139, GPR3, GPR84 GPR139 1/4885
US-20160145218-A1 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 GPR139, GPR3, GPR84 GPR139 1/4885
US-10561662-B2 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 GPR139, GPR3, GPR84 GPR139 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback